MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 70 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,073,327 | -25.9% | 1,872,463 | 0.0% | 3.72% | -10.0% |
| Q2 2023 | $20,334,948 | +57.4% | 1,872,463 | 0.0% | 4.13% | +49.7% |
| Q1 2023 | $12,919,995 | +73.4% | 1,872,463 | 0.0% | 2.76% | +70.1% |
| Q4 2022 | $7,452,403 | -15.3% | 1,872,463 | +41.6% | 1.62% | -11.7% |
| Q3 2022 | $8,794,000 | +37.4% | 1,322,463 | 0.0% | 1.84% | +38.8% |
| Q2 2022 | $6,401,000 | -48.2% | 1,322,463 | 0.0% | 1.32% | -39.7% |
| Q1 2022 | $12,365,000 | -2.0% | 1,322,463 | +24.5% | 2.19% | +11.4% |
| Q4 2021 | $12,623,000 | +4.4% | 1,062,500 | 0.0% | 1.97% | +0.3% |
| Q3 2021 | $12,091,000 | -36.6% | 1,062,500 | 0.0% | 1.96% | -31.7% |
| Q2 2021 | $19,061,000 | -25.8% | 1,062,500 | -36.0% | 2.88% | +31.1% |
| Q1 2021 | $25,694,000 | +195.6% | 1,659,820 | +133.0% | 2.19% | +29.6% |
| Q4 2020 | $8,692,000 | +16.5% | 712,500 | +22.7% | 1.69% | +26.7% |
| Q3 2020 | $7,459,000 | – | 580,462 | – | 1.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |